Evidence map›Paper›PMID 27769206›Full record

ArticleBMC public health2016

Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.

Katsiaryna Holl, Christophe Sauboin, Emanuele Amodio, Paolo Bonanni, Giovanni Gabutti

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Varicella zoster virus vaccines: an update.ImmunoTargets and therapy · 2019
    Article
  17. Article
  18. Varicella vaccination - the global experience.Expert review of vaccines · 2017
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Katsiaryna HollGSK Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium. Katsiaryna.x.holl@gsk.com.
Christophe SauboinGSK Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium.
Emanuele AmodioUniversity of Palermo, Via Del Vespro 133, 90127, Palermo, Italy.
Paolo BonanniUniversity of Florence, Viale GB Morgagni, 48, 50134, Florence, Italy.
Giovanni GabuttiUniversity of Ferrara, Via Fossato di Mortara 64b, 44121, Ferrara, Italy.
GlaxoSmithKline (Belgium) · BEASST Melegnano e della Martesana · ITUniversity of Ferrara · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaricella is a highly infectious disease with a significant public health and economic burden, which can be prevented with childhood routine varicella vaccination. Vaccination strategies differ by country. Some factors are known to play an important role (number of doses, coverage, dosing interval, efficacy and catch-up programmes), however, their relative impact on the reduction of varicella in the population remains unclear. This paper aims to help policy makers prioritise the critical factors to achieve the most successful vaccination programme with the available budget.

methodsScenarios assessed the impact of different vaccination strategies on reduction of varicella disease in the population. A dynamic transmission model was used and adapted to fit Italian demographics and population mixing patterns. Inputs included coverage, number of doses, dosing intervals, first-dose efficacy and availability of catch-up programmes, based on strategies currently used or likely to be used in different countries. The time horizon was 30 years.

resultsBoth one- and two-dose routine varicella vaccination strategies prevented a comparable number of varicella cases with complications, but two-doses provided broader protection due to prevention of a higher number of milder varicella cases. A catch-up programme in susceptible adolescents aged 10-14 years old reduced varicella cases by 27-43 % in older children, which are often more severe than in younger children. Coverage, for all strategies, sustained at high levels achieved the largest reduction in varicella. In general, a 20 % increase in coverage resulted in a further 27-31 % reduction in varicella cases. When high coverage is reached, the impact of dosing interval and first-dose vaccine efficacy had a relatively lower impact on disease prevention in the population. Compared to the long (11 years) dosing interval, the short (5 months) and medium (5 years) interval schedules reduced varicella cases by a further 5-13 % and 2-5 %, respectively. Similarly, a 10 % increase in first-dose efficacy (from 65 to 75 % efficacy) prevented 2-5 % more varicella cases, suggesting it is the least influential factor when considering routine varicella vaccination.

conclusionsVaccination strategies can be implemented differently in each country depending on their needs, infrastructure and healthcare budget. However, ensuring high coverage remains the critical success factor for significant prevention of varicella when introducing varicella vaccination in the national immunisation programme.

Indexed as

AdolescentBudgetsChickenpoxChickenpox VaccineChildFemaleHumansImmunization ProgramsItalyMaleMass VaccinationModels, TheoreticalNational Health ProgramsVaccinationVaccines, AttenuatedChickenpox VaccineVaccines, AttenuatedCoverageDosing intervalEfficacyRoutine varicella vaccination impactVaricella

Identifiers

PMID27769206
PMCPMC5073465
OpenAlexW2534128483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.